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The main pathological features in the Alzheimer’s brain are progressive depositions of amyloid protein plaques among nerve cells, and
neurofibrillary tangles within the nerve cells. The major components of plaques are Aβ peptides. Numerous reports have provided evidence that Aβ
peptides are cytotoxic and may play a role in the pathogenesis of AD. An increasing number of research reports support the concept that the Aβ–
membrane interaction event may be followed by the insertion of Aβ into the membrane in a structural configuration which forms an ion channel. This
review summarizes experimental procedures which have been designed to test the hypothesis that the interaction of Aβwith a variety of membranes,
both artificial and natural, results in the subsequent formation of Aβ ion channels We describe experiments, by ourselves and others, that support the
view that Aβ is cytotoxic largely due to the action of Aβ channels in the cell membrane. The interaction of Aβwith the surface of the cell membrane
may results in the activation of a chain of processes that, when large enough, become cytotoxic and induce cell death by apoptosis. Remarkably, the
blockage of Aβ ion channels at the surface of the cell absolutely prevents the activation of these processes at different intracellular levels, thereby
preserving the life of the cells. As a prospect for therapy for Alzheimer’s disease, our findings at cellular level may be testable onAD animal models to
elucidate the potential role and the magnitude of the contribution of the Aβ channels for induction of the disease.
Published by Elsevier B.V.
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The discovery of the ion channel activity of amyloid-beta
(Aβ) peptides, and its possible relevance to the pathogenesis of
Alzheimer's disease (AD), dates back to our discovery of Aβ
channels in 1993 [1]. AD is a progressive neurodegenerative
disorder characterized by irreversible cognitive and physical
deterioration. The main pathological features in the Alzheimer's
brain are progressive depositions of amyloid protein plaques
between nerve cells and neurofibrillary tangles within the nerve
cells [2]. The major components of plaques are Aβ peptides of
up to 43 amino acids. These peptides are produced from a
transmembrane protein, the amyloid precursor protein (APP), by
the activity of specific enzymes [3–5]. Numerous reports have
provided evidence that Aβ peptides are cytotoxic andmay play a
role in the pathogenesis of AD [6–9]. Consequently, it has been
hypothesized that the primary cause of cellular damage and
degeneration in AD brain may be a toxic interaction between Aβ
peptides and nerve cells [10]. However, Aβ is not a pathological
product itself. Rather it is made continuously and normally by
most cells in the body throughout life [11]. Aβ is also released
from cultured cells during normal metabolism [3,12,13].
Although there is no question that the inappropriate accumula-
tion of cerebral amyloid plaques is a hallmark of Alzheimer's
disease, the importance of this accumulation for the onset and
progression of the disease is less clear. In fact, recent evidence
suggests that the content of soluble oligomers of Aβ in the
human brain is actually better correlated with the severity of the
disease than is the occurrence of the classical macroscopicFig. 1. Schematic of major steps in the life of the enzymatically liberated Aβ peptide and
protein, APP, into the medium. (2) Some of the extracellular Aβ could be taken up into th
However, in Alzheimer's disease brain the Aβ released into the extracellular fluid aggr
channels in cells. (5) In vitro,whenAβ is added to cell culturemedia or ionic solutions, the
of Aβ, are converted into small and large aggregates, protofibrils and fibrils enriched ofamyloid plaques containing insoluble Aβ deposits [14,15].
Furthermore, soluble oligomers, rather than insoluble plaque
assemblies, are the apparent causes of learning and memory
deficits in animal models of Alzheimer's disease [16,17].
Fig. 1 schematically summarizes some of the major steps in
the life of the enzymatically liberated Aβs peptides and their
action on cells. Normally, Aβ is released into the body fluids
where it can remain in the non-toxic non-aggregated state.
However, in a cell culture medium or in an ionic solution, Aβ
will convert from random coil and α-helical structure
characteristic of the non-aggregated state of Aβ into small
and large aggregates, protofibrils and fibrils. These aggregates
are enriched in more toxic β-sheet structures. The schematic
shows, as has been recently proposed, that the cellular damage
and degeneration induced by external Aβ in Alzheimer's
disease may occur either by the formation of harmful Aβ ion
channels [18,19], or by the interaction of the soluble oligomers
of Aβ with the neuronal membrane [20].
When a suspension of Aβ peptides is added to cells in
culture, Aβ molecules immediately interact with the surface of
cells and remain tightly attached. The fluorescence images and
associated histograms shown in Fig. 2 illustrate this phenom-
enon. The images in this figure are of PC12 cells that were
exposed for a brief period of time to FITC-conjugated Aβ42.
The Aβ42 was then removed from the medium, and cells were
analyzed for bound ligand by fluorescent microscopy and flow
cytometry. The images were taken either immediately or 24 h
after a 2-h exposure to Aβ. For this experiment Aβ-FITC was
removed from the external medium, and promptly washed threeits action on cells. (1) Physiologically, the Aβ peptide is released from the precursor
e cell. (3) Most Aβ remains in the medium in the non-toxic non-aggregated state. (4)
egates to form neuritic plaques, soluble oligomers and structures that can form ion
basically randomcoil and helices structures, characteristic of the non-aggregated state
β sheet structures.
Fig. 2. Aβ interacts tightly with cell membranes. When Aβ is externally added and interacts with the surface membrane of cells, Aβ molecules remain tightly
membrane-attached resisting medium changes (washing). PC12 cells were exposed for a 2-h period to 15 μM Aβ42 conjugated to the fluorescent probe FITC. (A)
After cells were washed and Aβ–FITC removed from the external medium, the images of the cells were taken either immediately or 24 h later. The residual
fluorescence on the surface of cells indicates that Aβ was still bound to the cells. (B) The histograms of cell distribution analyzed by flow cytometry show no
fluorescence (<1%) on the surface of control non-exposed cells (green curve). In contrast, the distribution of cells exposed to Aβ showed residual fluorescence
immediately (87% of the cells, red curve) and 24 h (20% of the cells, blue curve) after the removal of Aβ–FITC.
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surface of cells suggests that Aβ42 is still bound to the cells.
The histograms confirm that the fluorescent signal from FITC–
Aβ42 is also detected when these cells are analyzed in parallel
by flow cytometry. Thus, despite the profound washing process,
Aβ molecules still remain tightly bound to the surface of the
cells.
There have been many previous compelling demonstrations
that cells exposed to Aβ respond with an increase in intracellular
calcium that depends on the calcium in the extracellular medium
[20–27]. Years of research have supported the concept that
disturbances of intracellular calcium homeostasis may be playing a
pathological role in the neurodegeneration associated with
Alzheimer's disease [24,28,29]. These experiments suggest that
one of the consequences of the interaction of Aβ with the cell
membrane is the generation of a calcium influx process that could,
if extensive enough, create disturbance in intracellular calcium
homeostasis.
A variety of interpretations have been proposed to explain the
molecular mechanism(s) by which Aβ interaction with cells could
result in calcium influx. Some investigators have proposed that the
first step involves interaction of Aβ with specific proteinaceous
membrane components, resulting in activation of a calcium influx
[21,30,31]. Others have postulated that the ion flux occurs when
Aβ directly interacts with components in the lipid bilayer matrix of
the plasma membrane, resulting in either unselective disruption of
the membrane permeability [20,32], or the formation of selective
ionic pathways [18,19].
2. Aβ interaction with membranes
2.1. Search for candidate membrane protein receptors for Aβ
The identity of a membrane protein receptor for Aβ has been
a quest for many years [33,34]. Several candidate cell surfacereceptors have been considered, these include tachykinin
receptors [35,36], serpin–enzyme complex (SEC) receptors
[37,38], integrins; P75 neurotrophin receptor; and receptor for
advance glycosylation end-products (RAGE) [39]. However,
the available supportive evidence remains problematic. The
data either question whether the interaction of Aβ with these
receptors actually results in calcium influx and Aβ neurotoxi-
city, or whether additional neuronal binding sites are needed for
the Aβ–neuron interaction [25–27,40]. Alternatively, it has
been conjectured that Aβ may directly interact with existing
voltage or ligand-gated calcium channels on the surface of the
cell membrane, thereby potentiating the toxic effects of
neuronal insults from excitatory amino acids [21,30,31].
However, this alternative has been questioned on two bases:
firstly, the kinetic bases for the Aβ-induced intracellular
calcium increase are inconsistent [20,22]. Secondly, cells
exposed to Aβ continue to die even after surface calcium
channels have been blocked by very specific and effective
channel blockers. Such blockers include ω-conotoxin, nifedi-
pine, verapamil, D-APV, bicuculline, MK-801, cAMP, 8-
bromo-cAMP, and cGMP [24,41]. However, the debate has
continued because of more recent reports that Aβ promotes
stimulation of calcium influx into cortical synaptosomes via
activation of L- and N-type voltage dependent calcium
channels, and by increases in the amplitude of N- and P-type
currents in cultured cortical neurons [42]. Yet, morphological
changes leading to cell degeneration induced by fresh and
globular Aβ42 cannot be prevented by Cd2+, which blocks
voltage-sensitive Ca2+ channels [25].
2.2. Search for non-protein components of the plasma
membrane that interact with Aβ
Alternative molecular mechanism(s) has been proposed to
explain how the Aβ interaction with cells results in calcium
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with non-protein components of the plasma membrane with
consequent disruption of membrane permeability [1,43,44].
One of these proposed mechanisms suggests that Aβ oligomers
increase the area per molecule of the membrane-forming lipids,
thus thinning the membrane, lowering the dielectric barrier and
increasing the conductance [44]. Another proposed mechanism
considers that following interaction with the membrane Aβ
inserts into the membrane and forms well-defined pores which
selectively increase the membrane ionic permeability [1]. The
existing evidence for Aβ penetration into the membrane
introducing a selective change of membrane conductance is so
overwhelming that the alternative to explain the altering of the
membrane conductance by Aβ due to destabilization without
membrane penetration and formation of ion channels, could just
be complementary and unspecific by nature. The possibility of
Aβ insertion into the membrane to form well-defined pores was
originated from the pioneering experiments performed by
Arispe et al. (1993) [1,45] which showed the appearance of
ionic current fluxes after Aβ incorporation into artificial
membranes. The possibility of penetration and disruption of
membrane permeability by Aβ has received additional support
by numerous reports of induced ion channel activity after
membrane exposure to Aβ [46,47,81–86,93,101,103–106].
The insertion of protein-forming pores into membranes can
be faithfully shown by following the changes in bilayer
capacitance and resistance. Using a dual sinusoidal current,
Vargas et al. [47] recorded Aβ-specific displacement currents
across a planar lipid bilayer in response to sudden changes in the
membrane potential after the membrane had been exposed to
Aβ. These data indicated that the pore-forming Aβ had been
inserted into the membrane. Most recent data from NMR
spectra and high sensitivity circular dichroism (CD) spectro-
scopy on model membranes also confirms this finding [48].
These studies showed that Aβ interacts with the phospholipid
head groups of the membrane where it can either remain in an
unstructured associated state or incorporate within the lipid
bilayer. When incorporated into the membrane Aβ adopts the
most toxic β-sheet structure disrupting the membrane more
severely than when unstructured Aβ is associated on the
membrane [48]. The adoption of this preferred β-sheet structure
when Aβ is incorporated into the membrane was one of the
bases for Durell et al. [68] to develop theoretical models of the
Aβ ion channel structure. The channel structures were designed
as aggregates of peptide subunits in identical conformations.
The secondary structure of the subunits was predicted to form a
β-hairpin followed by a helix–turn–helix motif. One of these
helices is embedded in the top head group layer of the
membrane with the other helix inserted into the membrane core.
The insertion of Aβ into cell membranes has also been modeled
by Mobley et al. [49]. Using a Monte Carlo code which is
specific at the amino acid level they examined the effect of
mutations on the Aβ peptide's insertion behavior. The results
indicated that mutations affect peptide insertion causing the
peptide to prefer (relative to wild-type) a conformation where
those residues are in the upper lipid head region. This causes the
peptide to hang up in the upper leaflet (the partially insertedconformation) and facilitates formation of channels. It is
interesting to note that a channel structure suggested previously
by Durell et al. (1994) has these mutated residues laying along
the surface of the bilayer. Thus Mobley et al. [49] find that
mutations increase the resemblance to the ion channel
configuration. The formation of well-defined pores presumes
that prior to the insertion in the membrane to form a pore the Aβ
must first selectively interact with the components in the surface
of the membrane. A series of findings indicate that the lipid
composition of the membrane governs the outcome of Aβ
interactions with cell membrane, and the effectiveness of this
interaction will depend on the structural conformation of Aβ.
Initially, the structural conformation of Aβ in solutions is
characterized by a concentration-dependent equilibrium of
mixture of β-sheet, α-helix and random coil conformations.
In the presence of some lipids, the equilibrium may be shifted
towards preferred states of conformation. For instance, the
contact with neutral lipids does not affect the conformation of
Aβ in solutions, and Aβ does not seem to interact with
membranes formed of neutral phospholipids [47,50–52]. This
assertion was validated by using compounds that decrease the
effective negative charge of membranes [53]. The decrease in
the negative charge of the membrane prevents the Aβ
association as well as the subsequent cellular degeneration
induced by Aβ. Therefore, these results suggest that negatively
charged lipids are required to establish an effective Aβ–lipid
interaction. These findings could be interpreted to indicate that
Aβ toxicity is initiated by a nonspecific physicochemical
interaction of Aβ with cell membranes. In any case, the Aβ–
membrane interaction which precedes the insertion in the
membrane would preferentially be a specific electrostatic
interaction of Aβ with acidic phospholipids of negatively
charge membranes [51,53,54]. Because positively charge
aminoacids are necessary for the interaction with negatively
charged phospholipids, it has been suggested that lysine residues
in the sequence of Aβ may provide the site of association with
the phospholipids in the cell membrane [55,56]. The sequence of
Aβ possesses lysine residues at positions 16 and 28; therefore, it
may be possible that Aβ molecules would interact with the
membrane at these two possible sites. Compelling data suggest
that the phospholipid phosphatidylserine is very likely to be the
elusive membrane surface receptor site for Aβ binding
[52,57,58]. However the possible association of the lysine
residues in the Aβ molecule with membrane localized
phosphatidyl serine as interactive site with the lipid matrix of
the membrane is yet to be confirmed.
The interaction of Aβ with other non-protein components
of the plasma membrane, such as monosialoganglioside GM1
and cholesterol has been a subject of intense investigation.
These studies have addressed the fundamental question about
the conversion of elemental units of Aβ into its toxic
aggregates. Nevertheless, they have not yet been able to
explain the molecular mechanism(s) by which Aβ interaction
with cells could result in calcium influx. However, since we
have proposed that when Aβ molecules assemble into
conducting channels under the appropriate structural circum-
stances, the interaction between Aβ and the surface of the cell
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consequently permit calcium influx. The findings, in summary,
show that Aβ selectively recognizes a GM1 cluster in mem-
branes and binds to and accumulates on GM1-rich domains in
membrane in a time- and concentration-dependent manner
[59,60]. Yanagisawa et al. (1995) [61] identified a unique Aβ
peptide species in the AD brain which is characterized by its
binding to GM1 ganglioside. This species of Aβ was shown
to exhibit unique molecular characteristics with high aggrega-
tion potential. The discovery of this species led to the
hypothesis that Aβ adopts an altered conformation by binding
to GM1 and acts as a seed for the assembly of soluble Aβ
[62].
Cholesterol may also contribute to Aβ activity. It has been
shown that the ability of Aβ to insert into the membrane is
critically controlled by the ratio of cholesterol to phospholipids
[63]. Altering this ratio, by lowering the concentration of
cholesterol, results in Aβ staying on the membrane surface
region, mainly in a beta-sheet structure. In contrast, as the ratio
of cholesterol to phospholipids rises Aβ can spontaneously
insert, by its C terminus, into the lipid bilayer. A series of other
studies have shown that intramembrane cholesterol also
facilitates the formation of the GM1–Aβ complexes which
have been suggested to be the endogenous seed for Alzheimer
amyloid [59,61,62,64]. In fact, depletion of cholesterol in PC12
cells abolishes the formation of GM1-rich domains and
significantly reduces binding of Aβ [60]. Consistently, these
investigators propose that membrane binding by Aβ triggers its
conformational transition from helix-rich to β-sheet rich
structures [43,65,66], in contrast to membrane insertion which
generates alpha-helix and removes almost all β-sheet structure
[63]. Data obtained most recently by other investigators present
a different structure for Aβ inserted into membranes [48]. Aβ
incorporated into lipid bilayers, analyzed with Synchrotron
radiation CD which possesses a higher sensitivity and better
signal to noise ratio than conventional CD, has more β-sheet
structure compared to Aβ just associated with membranes. In
any case, all data suggest that the structure of Aβ aggregates in
membranes may be different from that of the protein aggregated
in solution [60,67]. We have proposed and modeled a polymeric
structure for the membrane bound Aβ which we suggest might
be the structure responsible for the formation of the Aβ ion
channel and the consequent intracellular calcium increase
[68,69].
In concert, all of these mechanisms have a common trajec-
tory towards the formation and activation of Aβ ion channels.
This molecular mechanism was proposed by Arispe et al., in
1994 and is known as the β-amyloid calcium channel hypo-
thesis. According to this hypothesis a selective increase of the
membrane ionic permeability involves Aβ interaction and
insertion into the membrane to form a selective cation channel
[1,18,19,45,46,70,71]. The hypothesis proposed that Aβ
forms minimal polymeric structures, possibly only hexamers,
which may directly interact with the neuronal plasma mem-
brane and form a conducting pore. We suggested that these
pores might be the basis for loss of neurons in Alzheimer
disease.3. Aβ forms calcium channels in artificial and natural
membranes
3.1. Aβ channels formed in planar lipid bilayers
The capacity of Aβ molecules to form ion channels was
originally proposed by Arispe et al. (1993) [1,45] from the
analysis of records of ionic current in artificial lipid membranes
exposed to solutions of Aβ. The idea that the Aβ peptide could
acquire the appropriate configuration to form ion channels in
membranes was instigated by two basic findings. First, it had
been shown that Aβ increased intraneuronal [Ca2+]i and
disrupted calcium homeostasis [8]. Cells exposed to Aβ
experienced a peak increase in the intracellular calcium
concentration that depended on the presence of calcium in the
extracellular medium. Second, it was observed that the first 16
residues of the Aβ molecule had the characteristic feature of
alternating charged or neutral residues with hydrophobic
residues capable of forming amphipathic beta-sheets. This
residue arrangement was consistent with amphipathic beta sheet
secondary structures, as occurs in other molecules that had been
shown to form ion channels. This was the case of molecules
such as porin/VDAC and shaker K [72,73], and some protein
members of the annexin gene family such as lipocortin I
(ANXA1), endonexin II (ANXA5) and synexin (ANXA7) [74–
80] which generate highly selective calcium channels.
The procedure to record current activity from membrane-
incorporated Aβ channels consisted of first incorporating Aβ
molecules from a freshly prepared water solution into a
suspension of pure phosphatidylserine liposomes. Proteolipo-
somes were used as a vehicle to facilitate the fusion with the
artificial phosphatidylserine-containing lipid bilayer, and to
prompt the incorporation of the Aβ ion channel in the
membrane. The liposomes containing the Aβ molecules were
added to one of the compartments of a chamber holding two
solutions separated by a planar lipid membrane made by a
mixture of artificial phospholipids dissolved in decane. Fig. 3A
schematizes the experimental arrangement and the ensuing
electrical currents that appear after a liposome-containing an Aβ
channel is fused with the planar lipid membrane. The Aβ
channel incorporated into the dividing planar lipid membrane
allows ions to flow between the two solutions, based on the
channel permeability and the ionic concentration gradient.
When a driving force is present, such as a membrane electrical
potential difference or an ionic concentration gradient, ions
move between the solutions and discrete current changes,
characteristic of ion channel activity, are observed. The Aβ
channels have been identified as cation channels by measuring
the direction of the shifts in the reversal potential of the ionic
currents when the ionic concentrations in the solutions are
changed, and the permeability sequence for cations was
established as PCs>PLi>PCa=PK>PNa [1]. Although the Aβ
channel was found to be permeable to different cations, the ion
permeation ceased if calcium in the micromolar range were
added. This property is characteristic of classical calcium
channels; therefore, the Aβ ion channel was regarded to be a
functional calcium channel. Nevertheless, the Aβ calcium
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pharmacological characteristics. For example Aβ channels are
insensitive to blockage by nifendipine, and are selectively
sensitive to blockage by zinc ions and tromethamine [45].
Membrane-free Aβ molecules in solutions, as one would
expect Aβ to be found in the body fluids, can also spon-
taneously interact and form cation selective channels with both
intracellular and extracellular aspects of both artificial [45,81–
83] and natural plasma membranes [84]. The planar lipid
membrane technology, as it was originally applied to describe
the ion channel properties of Aβ, is based on the use of
artificial membranes prepared from a mixture of phospholipids
dissolved in decane. This mixture is then applied in a small
orifice separating two ionic solutions. This procedure generates
the concern that some of the organic solvent used to dissolve
the phospholipid remains in the artificial membrane and may
affect the natural configuration of the channel-forming
molecules. During the discovery of the ability of Aβ to form
ion channels, unnatural molecular configurations of Aβ were
ruled out by the application of the pipette double dip method to
form the bilayer membranes [45]. This method consisted in
forming a phospholipid bilayer membrane at the tip of a patch
pipette which is double dipped into a solution with a monolayer
film made of synthetic phospholipids spread upon it. Fig. 3B
schematizes this procedure and shows the type of ionic channel
activity that appears in solvent-free membranes after the
addition of Aβ to the bathing solution. The ion channel
activity is similar both in character and in properties to the
channel activity observed from bilayers formed with phospho-
lipids in organic solvents. The results demonstrated beyond any
doubt that Aβ in solution can assume a conformation that
enables the molecule to enter the bilayer membranes and form
cation selective channels.Fig. 3. (A) Aβ forms ion channels in planar lipid bilayers. The drawing
schematizes the incorporation of an Aβ channel molecule into a planar
phospholipid bilayer. The incorporation is produced by the fusion of an Aβ-
carrying vesicle with the bilayer. The right panel shows actual current traces to
illustrate the characteristic Aβ channel activity. The chambers at the bottom
schematize the flow of charged particles through the open Aβ channel. This
flow of charged particles, driven by an electrochemical gradient, generates the
electrical current traces shown on the right panel of the figure. (B) Aβ forms ion
channels in solvent-free planar lipid bilayers. The drawing schematizes the
pipette double dipping procedure to form a solvent-free bilayer membrane. After
the membrane is formed at the tip of the pipette, Aβ is added to the external
solution to allow for spontaneous incorporation and formation of Aβ ion
channels. The current traces on the right are actual current traces after the
incorporation of an Aβ channel. The traces illustrate the characteristic current in
response to pulsed changes in the bilayer electrical potential of increasing
magnitude. The contribution of the current activity from the Aβ channel is
shown after specifically blocking the Aβ channel. The remaining currents are
the unspecific membrane leakage currents. (C) Aβ forms ion channels in patches
of natural membranes. Aβ forms ion channels in detached inside-out patches of
cell membrane after Aβ addition to either the solution inside the pipette or to the
external medium. The current traces at the right (a) are actual current activity
which appears after the addition of Aβ to the medium bathing an inside-out
patch of membrane detached from a GT1–7 cell. To confirm the source of the
current the effective Aβ channel blocker zinc was added to the external medium
(b). The current from the Aβ channel reappears after the blocker is removed
from the solution (c).3.2. Aβ channels formed in liposomes
Three dimensional systems such as unilamellar liposomes
have provided a very convenient way to confirm the formation of
ion selective pathways by Aβ. They have also provided a
convenient platform to study the pharmacological sensitivity of
the Aβ channel pathways, and the influence of the membrane
phospholipid content. Experiments performed on liposomes
prepared with mixture of natural phospholipids such as
phosphatidyl choline and phosphatidyl serine, showed signifi-
cant uptake of calcium ions after the liposomes were exposed to
solution containing Aβ molecules [85]. The formation of ion
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specifically blocking the channels with zinc ions and trometha-
mine, which had been shown to inhibit Aβ ion channels [1,70].
Similar liposome experiments using an antibody raised against
the amino-terminal domain of Aβ showed that the antibody
prevented the calcium uptake by liposome reconstituted with
Aβ, thus confirming the molecular identity of Aβ channels [86].
Dose-dependent Na+ and Ca2+ entry has also been observed
following the incorporation of Aβmolecules into the membrane
of vesicles of phosphatidyl serine loaded with fluorescent ion
indicators [52]. The stimulation of cation influx by Aβ required
that the liposomes be composed of at least a small amount of
acidic phospholipid. These results are in accord with previous
studies in planar lipid bilayer, and in neuronal membrane patches
which have demonstrated preferential formation of Aβ channels
in negatively charged membranes [1,84].
Changes in the mechanical properties of bilayers, such as
the Critical Lysis Tension of vesicles [87], accompanied by
changes in permeability to fluorescent probes have also been
observed in liposomes exposed to Aβ [88]. Vesicles of
different lipid composition loaded with fluorescence probes
and exposed to Aβ exhibit a decrease in fluorescence intensity
caused by a permeability change and consequent leak of the
fluorescent probe trapped inside the vesicles. When incorpo-
rated into the membrane Aβ also induces a strong destabiliza-
tion of the vesicle membrane, as detected by a dramatic
decrease in the critical tension needed for vesicle rupture.
These changes denote the ability of Aβ to associate with and
incorporate into the membrane, to reduce the lateral membrane
cohesive forces and to induce permeability changes [88].
NMR spectra of bilayers with incorporated Aβ also show that
Aβ incorporation into the bilayer has a more dramatic effect
on the lipid bilayer integrity than when Aβ simple associates
with the membrane. The Aβ incorporation produces a reduced
stability of the bilayer with the greatest effect observed in the
hydrocarbon core [48].
3.3. Aβ channels formed in natural membranes
Aβ molecules in solution also form ion channels in natural
membranes. Kawahara et al. [84] showed that excised
membrane patches from a cell line derived from hypothalamic
neurons produced new ion channel activity when exposed to
Aβ molecules. Patch-clamp experiments were performed in
membrane patches pulled from cultured neurons, and mem-
brane currents under voltage clamp conditions were recorded.
The Aβ-induced channel activity was observed after Aβ
interacted with either side of isolated patches of membranes.
Observation occurred sooner when the Aβ interacted with the
phosphatidylserine-richer inner side of the membrane. Fig. 3C
illustrates the experimental procedure and the ion channel
activity. For the formation of ion channels from the inner side
of the membrane, Aβ molecules were added to the external
cell medium of inside-out cell membrane patches. For the
formation of ion channels on the outer side of the membrane,
the Aβ molecules were placed inside the pipette solution. Both
types of experiments lead to the generation of ion channelactivity due to successful incorporation of Aβ molecules.
However, the faster observation of channel activity from the
phosphatidylserine-richer inner side of the membrane is
considered highly meaningful since it adds to the increasing
data endorsing the hypothesis that phosphatidylserine may be
the possible membrane surface receptor site for Aβ binding
[57]. Remarkably, the properties of the Aβ channels formed in
natural membrane are similar to those observed in artificial
bilayer membranes. For example, the Aβ channels in natural
membranes also show a cationic selectivity, frequent transi-
tions among different levels of conductance and sensitivity to
zinc ions. Previously we showed that zinc ions are very
effective blockers of the ionic flow through Aβ channels [70].
Although the formation of Aβ channels has been convin-
cingly demonstrated in artificial and natural patches of
membranes, technical considerations limit the unquestionable
demonstration of single channel activity from Aβ channels
incorporated in the membrane of a cell. The amount of current
flowing through a single channel is so small, less than 1 pA/pF,
that it is difficult to detect in a whole cell recording
configuration. However, compelling evidence for Aβ channel
formation in cells has been reported by selectively blocking the
calcium currents induced by Aβ in cells with specific Aβ
channels blockers. Peers and colleagues [89,90] found that
periods of chronic hypoxia, which induce enhancement of
calcium channels, led to the appearance of novel calcium-
conducting channels in PC12 cells. These channels could not be
prevented by Cd2+. However, they were blocked either by
Congo red or by an antibody raised against the N-terminal
region of Aβ. Similar intracellular calcium increases induced by
Aβ in fibroblasts and in GT1–7 hypothalamic neurons, were
selectively blocked by a specific antibody against Aβ [24,26].
In these cells, transient calcium currents persisted after addition
of Aβ to media containing of a variety of channel blockers,
including TTX, D-APV, nifedipine, and bicuculline. However,
Aβ calcium currents could not be observed when the antibody
to Aβ was also present in the media.
While the activity of small conductance Aβ channels formed
in the cell membrane can be managed by the cellular
homeostatic mechanisms, large conductance channels can be
deleterious to cells and generate increases in the intracellular
calcium levels associated with profound cytotoxicity [91]. In
our previous studies of Aβ channels in planar lipid membranes
we showed that Aβ channel conductance can spontaneously
interconvert among levels in both the picosiemens and the
nanosiemens range [45]. One might expect then that conver-
sions to the large nanosiemen conductance levels after an Aβ
channel has been formed in a cell membrane may have
profound consequences for cytosolic homeostasis.
4. Effect of specific Aβ ion channels blockers on Aβ
channel activity
4.1. Blockage of Aβ ion channels in planar lipid bilayers
The contribution of Aβ channels to the cytotoxic properties
of Aβ has been compellingly confirmed by specifically
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Based in the chemistry of the regions around the putative mouth
of the polymeric membrane-bound Aβ channel model, we have
designed a series of compounds that selectively block Aβ
channels incorporated in artificial membranes [69]. Addition-
ally, we have successfully tested them as blockers of Aβ
channels and Aβ cytotoxicity in cells [92,93]. The selectivity of
these compounds as blockers of Aβ channels arises from the
fact that they posses the complementary chemistry necessary to
establish an effective and selective interaction with Aβ. The
recordings shown in Fig. 4A illustrate the blocking effect of one
of these compounds to an Aβ channel was reconstituted in a
planar lipid bilayer. After developing a stable ion channel
activity, the specific blocker NA7 was added to the experi-
mental chamber. The chemical structure of NA7 partially copies
the sequence of the putative mouth of the Aβ channel [69]. We
have shown that peptides with sequence homologous to the hair
pin region of the model did not interfere with the Aβ
aggregation process [69]. Soon after NA7 was added to the
chamber the current flowing through the Aβ channel vanished.Fig. 4. (A) Blockage of Aβ ion channels in planar lipid bilayers. Activity from an A
recorded before and after the addition of the specific Aβ channel blocker NA7. An ele
driving force on the ions. The effect of the blocker on the channel activity is recorded
The current amplitude histograms from the channel activity displayed in the above cu
(B) Specific blockage of Aβ ion channels prevents the reduction in cell viability in
incubation in the presence of Aβ (15 μM) and Aβ plus the peptides NA3 and NA7. C
II from Roche Molecular Biochemicals). Aβ plus peptide NA7 completely protect
viability levels significantly similar to the one obtained with Aβ alone. (b) Dose–r
peptides against Aβ cytotoxicity. Peptide NA7 was able to fully protect PC12 cells aga
at less than 1 μg/mL.The amplitude histograms of the current events from the current
records before and after the addition of NA7 show the
progressive reduction of the current events, trending towards
zero until the electrical recording becomes silent.
4.2. Effect of specific blockade of Aβ ion channels and Aβ
cytotoxicity
The categorical results on the prevention of Aβ cytotoxicity
observed after the use of the highly effective and very selective
Aβ channels blockers, added further corroboration to the
formation of Aβ channels in the surface membrane of cells,
and appraised the participation of these channels in the
generation of those changes [92]. The experimental data
plotted in Fig. 4B clearly demonstrate that blocking the Aβ
channel also prevents the reduction in cell viability induced by
Aβ. The viability of PC12 cells was determined after 3 days of
incubation in the presence of Aβ (15 μM) and Aβ plus the
peptides NA7 or NA3. NA3 had previously been shown not to
affect Aβ channels incorporated in planar lipid bilayer [69].β ion channel incorporated into a planar lipid bilayer. The current activity was
ctrical potential gradient of 20 mV was imposed on the membrane to enhance the
1 and 3 min after the addition of the blocker (middle and bottom current trace).
rrent traces show the blocking effect on the different channel conductance levels.
duced by Aβ. (a) The viability of PC12 cells was determined after 3 days of
ell viability was measured using a colorimetric XTT assay (Cell Proliferation Kit
ed the cells from Aβ toxicity. By contrast, Aβ plus peptide NA3 showed cell
esponse experiment to evaluate the capacity of protection of the two different
inst Aβ toxicity at concentrations higher than 4 μg/mL, and with 50% protection
1960 N. Arispe et al. / Biochimica et Biophysica Acta 1768 (2007) 1952–1965The bar histograms in Fig. 4Ba show that Aβ alone
considerably reduces the cell viability. As expected NA3, in
combination with Aβ, was unable to protect cells from Aβ. By
contrast, Aβ plus native sequence NA7 completely protected
the cells from Aβ toxicity. The results of a dose–response
experiment are shown in Fig. 4Bb. The data indicate that
peptide NA7 fully protects PC12 cells from Aβ toxicity at
concentrations higher than 4 μg/mL. The 50% protection level
was seen at NA7 concentrations of less than 1 μg/mL. These
and other data [92] indicate that prevention of Aβ cytotoxicity
can be achieved by selective blockade of the Aβ channels.
A compelling demonstration that Aβ ion channel activity
initiates the mechanisms that generate increase in intracellular
calcium are provided by experiments in which Aβ is allowed
to form channels in the surface membrane of the cells in the
presence and absence of specific Aβ channel blockers. The
records of intracellular calcium levels taken from GT1–7
hypothalamic neurons are displayed in Fig. 5, and illustrate the
response of cells to Aβ. The changes in the level of calcium
were detected with a calcium imaging system, as changes in
the fluorescence levels of Fura-2AM loaded cells. Cells
responded within seconds after the addition of Aβ with highly
diverse transients in intracellular calcium (see selected records
from a set of 79 cells in top panel). The amplitude and the
time course of the [Ca2+]i changes in each cell sum to what
could be expected from the formation of a random number of
multiconductance Aβ calcium channels. However, when the
medium contained a selective Aβ channel blocker, bottom
panel, just a few cells responded with minor changes in the
intracellular calcium levels of (see records in bottom panel).Fig. 5. Blockage of Aβ ion channels in the cell surface membrane stops Aβ-
induced intracellular calcium increase. Cells were plated on glass coverslips and
loaded with calcium-sensitive probes using media containing FURA-2AM
(Molecular Probes). Changes in the emission from Fura-2AM were observed
using an inverted epi-fluorescence/phase contrast microscope connected to a
calcium imaging system (InCyt I/P-2 TM Imaging and Photometry System,
Intracellular Imaging INC). Aβ was added to the medium bathing the GT1–7
cells and induced diverse transient increases in intracellular calcium. When the
medium contained the Aβ ion channel blocker peptide NA7, bottom panel, most
cells showed no response to Aβ, and a low percentage of cells responded with
minor intracellular calcium changes. For each condition (Aβ and Aβ+NA7),
the inserted table shows the percentages of cells that respond with increases in
intracellular calcium within <20, 20–70 and >70 nM.These results lead to the conclusion that when the ionic flow
through the Aβ channels is blocked, the acute increase in the
intracellular calcium level induced by Aβ does not occur.
It has been suggested that imbalance of the intracellular
calcium homeostasis mediates neurotoxicity of Aβ [21].
Although the specific intracellular signaling pathways by
which Aβ triggers cell death are not yet well defined, recent
studies have shown that in cells exposed to Aβ, the dying cells
display the characteristics of apoptosis [94–98]. With the
knowledge that the interaction of Aβ with cells conducts to
the formation of Aβ channels and a consequent calcium influx, a
valid strategy to evaluate the participation of the Aβ channels in
the degeneration of cells is to target the Aβ ion channels. This
action has been made available with the successful design of
specific Aβ channel blockers [69,93]. It would be expected that
by blocking the Aβ channels the events that characterize the
development of apoptosis can be prevented. A number of
independent assays have been developed to evaluate the distinct
mechanisms that characterize apoptosis. The loss of Phospha-
tidyl Serine (PS) membrane asymmetry is one of the earliest
signs of apoptosis while DNA fragmentation, a process that
results from the activation of endonucleases, is one of the later
steps. The activation of some members of the caspase family of
proteases also mediates events associated with apoptosis. Cell
death by apoptosis has also been evaluated by the quantification
of plasma membrane damage, such as the release of lactase
dehydrogenase (LDH) from the cytosol into the media, which
estimates the integrity of the cell membrane. Our published data
[92] demonstrated that in addition to morphological changes and
intracellular calcium increase, cells exposed to Aβ show
reduction in the number of metabolically active cells, increased
release of lactase dehydrogenase (LDH) from the cytosol, loss of
PS membrane asymmetry, and activation of caspase-3/7. The
involvement of the Aβ channels in the mechanisms that activate
all these intracellular events was demonstrated by the specific
blockage of Aβ channels. The compiled series of results shown
in Fig. 6 are evidence of this statement. The specific Aβ channel
blocker NA7 [67] was used in these experiments. We have
shown that this type of peptide blocker is totally innocuous to
cells and do not participate in any other manipulations that
induce apoptosis (92). PC12 cells were exposed for 24 h to Aβ in
the presence and in the absence of NA7 in the culture medium
and assays to detect the release of lactase dehydrogenase (LDH)
from the cytosol into the media, the activity of caspase 3/7, the
presence of PS in the external surface of the cell membrane and
the fragmentation of DNA, were applied. The extraordinary
elimination of any sign of activation by Aβ of the characteristic
mechanisms of apoptosis, after the specific blockage of the Aβ
channels, remarkably and unquestionable demonstrate the
critical role played by Aβ channels in the characteristic
cytotoxicity of Aβ.
5. Concluding remarks
This review summarizes a set of experiments, by us and
others, that compellingly suggest that Aβ is cytotoxic largely
due to the action of Aβ channels in the cell membrane. When
Fig. 6. Blockage of Aβ ion channels in the cell surface membrane stop events that characterize the development of apoptosis. (A, B) PC12 cells were exposed for 24 h
to 4 μM Aβ40 in the absence and presence of NA7 in the culture medium at the concentrations indicated at the bottom of the plots. The level of LDH release and
caspase 3/7 activation was evaluated using colorimetric assays (Cytotoxicity Detection Kit-LDH, Roche and CellProbe HT caspase 3/7 whole cell assay kit, Beckman
Coulter). Increasing concentrations of the Aβ channel blockers NA7 effectively reduced the LDH release and the levels of caspase activity to the value of the untreated
control cells. (C, D) To determine surface membrane phosphatidylserine (PS) PC12 cells were stained with AnnexinV-FITC followed by flow-cytometric analysis. To
measure DNA fragmentation, cells were incubated with Br-dUTP and detected with FITC-labeled anti-Br-dU mAb and PI by flow cytometry. Cells were exposed for
48 h to 4 μM Aβ40 in the absence and in the presence of NA7 in the culture medium. The histograms of the AnnexinV-FITC signal distribution, c, show that by
comparison to the control, the Aβ-treated cell population has an additional peak at higher intensity levels, indicating higher amount of PS on the outer surface
membrane of these cells. The detection of this extra peak is suppressed when the experiment is performed in the presence of the Aβ channel blocker peptide NA7. The
histograms of the anti-Br-dU-FITC signal distribution, d, show that by comparison to the control, the Aβ-treated cell population has an additional peak at higher
intensity levels, indicating higher amount of fragmented DNA. The detection of this extra peak is suppressed when the experiment is performed in the presence of the
Aβ channel blocker peptide NA7.
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appropriate structural configuration, the interaction with the
surface of the cell membrane results in the activation of a chain
of processes that, when large enough, become cytotoxic and
induce cell death by apoptosis [94–98]. In this interaction the
membrane of the cell plays a major role in providing the
necessary “receptor(s)” to facilitate the effective Aβ–membrane
interaction. Most of the searches to this moment identify non-
proteinaceous membrane components as the most likely
candidates for receiving and lodging Aβ within the cell
membrane [52,55–58,61,62,66]. Moreover, an increasing
number of research reports are supporting the concept that the
Aβ–membrane interaction event is followed by the insertion of
Aβ into the membrane in a structural configuration which may
form an ion channel [1,18,19,25–27,45,46,70,81,83,85,86,99–
106]. The consequent activity of this channel is the activation of
processes that, when uncontrolled, will conduct the cells to the
irreversible degeneration. Experiments shown here and else-
where [92,93] confirm that six of the most relevant cellularprocesses when activated by Aβ lead the cell to die by
apoptosis. On the contrary, none take place when the ion
channels formed by Aβ on the cell surface membrane are
selectively blocked. The schematic described in Fig. 7
summarizes some routes to activate these classical pre-apoptotic
processes which eventually produce irreversible cell damage.
Remarkably, the blockage of Aβ ion channels at the surface of
the cell absolutely prevents the activation of these processes at
different intracellular levels, thereby preserving the life of the
cells despite the extracellular presence of the toxic Aβ spices. It
is our hypothesis that the formation of Aβ ion channels in the
cell surface membrane contributes to the creation of a toxic
ionic imbalance, and that the failure of the intracellular calcium
homeostasis initiates the activation of the intracellular events
leading to cell degeneration.
A number of therapeutic approaches to reduce the burden
imposed by the presence of Aβ and its toxic forms in the
Alzheimer's brain have been tested. Some of them include
immuno-therapy agents, procedures to prevent Aβ generation
Fig. 7. The blockage of Aβ ion channels at the surface of the cell, completely prevents the activation of pre-apoptotic processes which eventually produce irreversible
cell damage. The schematic shown in this figure summarizes routes (green arrows) to six classical pre-apoptotic indicators (encircled) which experiments have shown
are activated or increased when cells are exposed to external Aβ, and the newly formed Aβ channels which allows calcium ions to enter the cell. Collectively, our
experiments show that when the Aβ channel formed at the surface of the cell is selectively blocked (black cross on the Aβ channel), the entry of calcium ions is
prevented and the activation of any of these processes does not occur (dotted crosses).
1962 N. Arispe et al. / Biochimica et Biophysica Acta 1768 (2007) 1952–1965from its precursor protein APP employing secretase modulators,
clearance of existing Aβ from critical areas of the brain, and
prevention of fibril formation by Aβ. At one time, it seemed
likely that the selective inhibition of aggregation, and fibril and
plaque formation by Aβ would provide a rational pharmacolo-
gical tool for the design of drugs useful for the treatment of
Alzheimer's disease. However, the results from the application
of these procedures to AD have not been encouraging [107–
109]. Indeed, recent experiments show persistent amyloidosis
following suppression of Aβ production in a transgenic AD
animal model [110]. This suggests that the clearance procedure
may not be applicable to relief of AD patients from human
amyloid since all patients are believed to enter therapies with at
least existing brain Aβ plaque burden. Moreover, it has been
shown that rodents made transgenic for human Aβ develop
amyloid deposits but do not lose the neurons that are central to
Alzheimer's disease [111]. Furthermore, irreversible structural
changes [25] and early apoptosis [92] have been observed in cells
exposed to fresh Aβ, long before Aβ forms fibrillar aggregates.
These results suggest that other mechanisms in addition to Aβ
aggregation are required to initiate the cascade of neurotoxic
events that characterize the possible role of Aβ in AD. Despite
intense effort, as of yet, no clinically relevant neuroprotective
strategy has emerged by following this approach.
Based on our own studies, prevention of the toxic effects of
Aβ on cells following exposure to Aβ, cannot be achieved byremoving Aβ from the solution bathing the cells [92]. Rather it
is necessary to selectively prevent the ionic fluxes through
newly formed Aβ channels. Relevantly, if the Aβ channel
blockers have been present in the cell culture media prior the
formation of Aβ channels, long-term cytotoxic effects fail to
occur. We have successfully developed effective and specific
Aβ ion channels blockers that have permitted us to disclose
the contribution of Aβ ion channels in cell degeneration
induced by Aβ. As a prospect for therapy for Alzheimer's
disease, our findings at cellular level remain to be extended
into reliable AD animal models to elucidate the role and the
magnitude of the contribution of the Aβ channels in induction
of the disease.
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